[CYTR] CytRx Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.39 Change: 0 (0.49%)
Ext. hours: Change: 0 (0%)

chart CYTR

Refresh chart

Strongest Trends Summary For CYTR

CYTR is in the medium-term down -60% below S&P in 1 year. In the long-term down -93% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company?s product candidate includes aldoxorubicin that has completed Phase IIb clinical trial as a first-line therapy for soft tissue sarcomas; and has initiated an international Phase II clinical trial in patients with late-stage glioblastoma multiforme, and a Phase II clinical trial in HIV-related Kaposi?s sarcoma. It also develops aldoxorubicin, which is in Phase Ib/II clinical trial primarily in the same indication, a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and is in Phase IIb pharmacokinetics clinical trial in patients with metastatic solid tumors. In addition, the company has evaluated a drug candidate bafetinib, in the ENABLE Phase II clinical trial in high-risk B-cell chronic lymphocytic leukemia. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-70.91% ROE-101.03% ROI
Current Ratio3.24 Quick Ratio Long Term Debt/Equity Debt Ratio0.42
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities30.55 M Cash From Operating Activities-23.94 M Gross Profit
Net Profit-11.69 M Operating Profit-14.2 M Total Assets62.63 M Total Current Assets60 M
Total Current Liabilities20.27 M Total Debt Total Liabilities20.27 M Total Revenue
Technical Data
High 52 week1.2 Low 52 week0.26 Last close0.27 Last change-0.74%
RSI32.79 Average true range0.03 Beta0.8 Volume1.06 M
Simple moving average 20 days-5.52% Simple moving average 50 days-10.34% Simple moving average 200 days-38.87%
Performance Data
Performance Week1.13% Performance Month-7.59% Performance Quart-18.76% Performance Half-52.14%
Performance Year-76.49% Performance Year-to-date-40.29% Volatility daily3.93% Volatility weekly8.79%
Volatility monthly18.02% Volatility yearly62.43% Relative Volume295.72% Average Volume36.27 K
New High New Low

News

2020-06-01 09:00:00 | CytRx Corporation Highlights Orphazyme's Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C

2020-05-26 09:00:00 | CytRx Corporation Highlights Orphazyme's Receipt of FDA Fast Track Designation for the Development of Arimoclomol in Amyotrophic Lateral Sclerosis ALS

2020-05-21 09:00:00 | CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin

2020-04-29 09:00:00 | CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Orphazyme A/S in Niemann-Pick Disease

2020-03-10 09:00:00 | CytRx Corporation Provides Update on Management Change

2020-02-28 09:00:00 | CytRx Corporation Clarifies Certain Prior Disclosures Regarding its Relationship with Orphazyme A/S

2020-02-11 09:00:00 | CytRx Corporation Highlights Recently Published Data of its Licensee Orphazyme A/S Phase 2 Trial of Arimoclomol in the Treatment of Sporadic Inclusion Body Myositis sIBM

2020-02-04 09:00:00 | CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S

2020-01-29 09:00:00 | CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin

2019-12-19 09:00:00 | CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin

2019-08-09 09:00:00 | CytRx Corporation Reports Second Quarter 2019 Financial Results

2019-07-30 09:00:00 | CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C

2019-07-22 09:00:00 | CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

2019-06-27 08:00:00 | CytRx Corporation Discusses Near Term Value from Out-License Deals and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com

2019-06-26 09:00:00 | CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation

2019-06-21 16:52:00 | Nasdaq delists shares of FTD, Insys, others

2019-06-19 09:00:00 | CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C

2019-05-31 09:00:00 | CytRx Corporation to Commence Trading on OTCQB Venture Market

2019-05-15 09:05:40 | CytRx: 1Q Earnings Snapshot

2019-05-15 09:00:00 | CytRx Corporation Reports First Quarter 2019 Financial Results

2019-05-08 09:00:00 | CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer

2019-05-02 09:00:00 | CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S

2019-04-29 09:00:00 | CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S

2019-03-29 09:00:00 | CytRx Corporation Reports 2018 Financial Results

2019-03-12 09:00:00 | CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic ACDx, Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

2019-02-13 09:00:00 | CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor

2019-02-11 09:00:00 | CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy

2019-02-06 09:00:00 | CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C NPC Conducted by Arimoclomol Licensee Orphazyme A/S

2019-01-14 09:00:00 | CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial

2018-12-21 09:00:00 | CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic

2018-11-28 09:00:00 | CytRx Corporation to Present at the 11th Annual LD Micro Main Event

2018-11-23 08:10:00 | Report: Exploring Fundamental Drivers Behind Graphic Packaging Holding, QEP Resources, Inogen, CytRx, Voyager Therapeutics, and Daily Journal Corp. S.C. — New Horizons, Emerging Trends, and Upcoming Developments

2018-11-12 08:40:01 | Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems

2018-11-09 06:47:11 | Bet on Rising P/E Investing With These 5 Top-Ranked Stocks

2018-11-08 09:00:00 | CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting

2018-11-02 14:00:46 | Edited Transcript of CYTR earnings conference call or presentation 2-Nov-18 3:00pm GMT

2018-11-02 09:14:34 | CytRx: 3Q Earnings Snapshot

2018-11-02 09:00:00 | CytRx Corporation Reports Third Quarter 2018 Financial Results

2018-10-31 09:00:00 | Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline

2018-10-29 09:00:00 | CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018

2018-10-01 03:47:54 | Edited Transcript of CYTR earnings conference call or presentation 6-Aug-18 3:00pm GMT

2018-09-25 09:00:00 | CytRx Corporation to Present at the 2018 MicroCap Conference

2018-09-13 09:00:00 | CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S

2018-08-27 09:00:00 | CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018

2018-08-06 09:00:00 | CytRx Corporation to Host Earnings Call

2018-08-06 08:33:12 | CytRx: 2Q Earnings Snapshot

2018-08-06 08:30:00 | CytRx Corporation Reports Second Quarter 2018 Financial Results

2018-08-01 08:30:00 | CytRx Corporation Pays Off Balance of Outstanding Debt

2018-07-30 09:00:00 | CytRx Corporation to Hold Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018

2018-07-25 08:30:00 | CytRx Announces Centurion BioPharma Corporation's Filing of a Provisional Patent Application